Anna Gueiderikh

Anna Gueiderikh

Auto-generated profile, based on publicly available information

Anna Gueiderikh

Hôpital Européen Georges-Pompidou, APHP, 20, rue Leblanc, Paris 75015, France

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Science Advances
Verified
Journal Article
Open access
PDF file
AGAnna Gueiderikh
Anna Gueiderikh
FMFrédérique Maczkowiak-Chartois
Frédérique Maczkowiak-Chartois
GRGuillaume Rouvet
Guillaume Rouvet
SSSylvie Souquère-Besse
Sylvie Souquère-Besse
SASébastien Apcher
Sébastien Apcher
FRFilippo Rosselli
Filippo Rosselli
FANCA is a multitasking protein with essential functions beyond DNA repair in nucleolar homeostasis and ribosome biogenesis.

10 September 2025 in Cancer/Radiothérapie
Verified
Journal Article
Open access
AGAnna Gueiderikh
Anna Gueiderikh
MMMorgan Michalet
Morgan Michalet
CDCatherine Dejean
Catherine Dejean
USUlrike Schick
Ulrike Schick
CDCatherine Durdux
Catherine Durdux
YKYoulia Kirova
Youlia Kirova
We present the updated recommendations of the Société française de radiothérapie oncologique (SFRO, the French society for radiation oncology) on radiotherapy and pregnancy. The occurrence of cancer during pregnancy is a rare event (approximately 1 in 1000 pregnancies). The risks for the embryo or the foetus depend on the gestational age at the time of irradiation. The main risks are malformations with microcephaly and mental retardation. There is also a risk of radiation-induced cancer in the unborn child. In the case of only supradiaphragmatic irradiation, radiotherapy can be performed most often in pregnant women without risk to the foetus. On the other hand, in the case of an indication for subdiaphragmatic irradiation, therapeutic termination of the pregnancy should be proposed. In all cases, when radiotherapy is chosen, a phantom estimation of the dose delivered to the foetus, confirmed by in vivo measurement, is recommended. Conformational radiotherapy is the preferred technique because of the lower dose delivered to the foetus (except for tumour locations where other techniques such as intensity-modulated radiotherapy are recommended).

16 May 2026 in Clinical and Translational Radiation Oncology
Verified
Journal Article
Open access
AGAnna Gueiderikh
Anna Gueiderikh
APAdrien Panis
Adrien Panis
SKSylvain Klotz
Sylvain Klotz
DMDamien Moreau
Damien Moreau
YMYannis Meraouna
Yannis Meraouna
PGPhilippe Giraud
Philippe Giraud
Kidney transplant candidates increasingly present with localized or locally advanced prostate cancer. While radiotherapy is frequently indicated, current planning guidelines do not account for the surgical constraints of future kidney transplantation. This study proposes a practical planning framework by defining transplant-specific organs at risk (OARs) and evaluating the dosimetric impact of their systematic optimization during prostate cancer radiotherapy. Through multidisciplinary collaboration between radiation oncologists and transplant surgeons, transplantation-critical structures were identified and delineated, including the bladder dome, ureters, and peri-vascular iliac fat. A comparative dosimetric analysis was performed across six planning strategies applied to two representative anatomical situations reflecting different bladder volumes: prostate-only Intensity Modulated Radiation Therapy (IMRT) with and without transplant-specific OARs optimization, stereotactic body radiotherapy (SBRT), and prostate plus pelvic nodal IMRT with and without optimization. Dose metrics to transplant-specific and conventional OARs were analyzed. In prostate-only treatments, active optimization of transplant-specific OARs resulted in a threefold or greater reduction in mean dose to the bladder dome, without compromising target coverage or increasing doses to conventional OARs. Similar dose reductions were observed for ureters and peri-vascular iliac external fat. SBRT achieved the lowest absolute doses to all transplant-specific OARs. In contrast, when pelvic lymph nodes were included, optimization failed to meaningfully reduce doses, with mean values exceeding 20 Gy for several transplant-critical structures. This work establishes a planning framework for integrating kidney transplantation constraints into prostate cancer radiotherapy. Prostate-only radiotherapy allows effective sparing of transplant-critical structures through active optimization, whereas pelvic nodal irradiation inevitably exposes these structures to high doses despite optimization. These findings support transplant-oriented treatment planning and careful selection of pelvic irradiation in kidney transplant candidates.

25 October 2025 in Advances in Radiation Oncology
Verified
Journal Article
Open access
AGAnna Gueiderikh
Anna Gueiderikh
BLBaptiste Lhomel
Baptiste Lhomel
RSRenaud Schiappa
Renaud Schiappa
MBMédéric Barret
Médéric Barret
VFVictoria Ferrari
Victoria Ferrari
JDJérôme Doyen
Jérôme Doyen
This study aims to evaluate the cumulative equivalent dose in 2 Gy fractions (EQD2) to organs at risk and its potential correlation with toxicities in patients with locally advanced nonsmall cell lung cancer treated with very high mediastinal radiation therapy doses using mixed fractionation. Patients from a previously reported phase 1 trial (PMID: 29650404) were included (n = 26). They received a stereotactic boost (3 × 7-12 Gy) following chemoradiation therapy (cisplatin-based chemotherapy and 23 × 2 Gy using three-dimensional conformal radiation therapy). Seventeen treatment plans were available for dosimetric analysis. Doses delivered at each point of the planning computed tomography scan from each treatment phase were converted to EQD2 based on the α:β ratios, which are shown in asterisks following each converted dose. The 3-dimensional conformal radiation therapy and stereotactic body radiation therapy plans were each converted to EQD2, and their summation was used to estimate the total dose delivered to organs at risk. In the entire cohort (n = 26), 77% of tumors were ultracentral, 19% peripheral, and 4% central. We observed 1 grade 3 toxicity (bronchial stenosis/fibrosis), 1 grade 4 toxicity (esophagitis with fistula), and 1 grade 5 toxicity (fatal hemoptysis). Dosimetric evaluation of the proximal bronchovascular (PBV) tree and esophagus revealed no severe late toxicity with PBV tree D1cc < 150 Gy *2* and esophageal D1cc < 100 Gy *10*. Median maximal EQD2 D1cc for organs at risk were as follows: aorta, 84.3 Gy *3* (range, 53.3-190.6); pulmonary arteries, 136.9 Gy *3* (range, 47.2-232.3); superior vena cava, 70.6 Gy *3* (range, 16.2-192.8); pulmonary veins, 69.0 Gy *3* (range, 3.5-231); esophagus, 67.9 Gy *10* (range, 15.7-161); PBV tree, 153.4 Gy *2* (range, 20.3-235.9). The following preliminary dose constraints—PBV tree D1cc < 150 Gy *2* and esophageal D1cc < 100 Gy *10*—may be safe and are currently being prospectively evaluated in an ongoing phase 2 trial (NCT06627738). The correlation between toxicities and the degree of initial tumor infiltration of organs at risk requires further prospective evaluation.

3 August 2023 in Acta Oncologica
Verified
Journal Article
Open access
AGAnna Gueiderikh
Anna Gueiderikh
YKYoulia M Kirova
Youlia M Kirova